Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Bivalent FluMist in Healthy Adults
NCT00192127Phase 3Completed
- Sponsor
- MedImmune
- Start
- Aug 2004
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal) in influenza (2 arms), sponsored by MedImmune. Primary endpoint: Fever (Day 0-7). Started Aug 2004; status: completed.
02
Drugs
influenza vaccine (trivalent, inactivated) or influenza vaccine (live, attenuated, intranasal)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00192127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192127.